Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ProQR (PRQR)
NASDAQ:PRQR
Holding PRQR?
Track your performance easily
PRQR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.11 - $3.29
Previous Close$1.83
Volume158.66K
Average Volume (3M)106.33K
Market Cap
$149.47M
Enterprise Value$19.13M
Total Cash (Recent Filing)€118.92M
Total Debt (Recent Filing)€19.73M
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Nov 06, 2024EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding81,354,592
10 Day Avg. Volume72,900
30 Day Avg. Volume106,327
Standard Deviation0.33
R-Squared0.00357
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.53
Price to Sales (P/S)14.05
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5.00Price Target Upside177.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
ProQR News
PremiumCompany Announcements
ProQR Therapeutics N.V. Financial Performance Review
PremiumCompany Announcements
ProQR Shareholders Approve Key Resolutions
PremiumCompany Announcements
ProQR Therapeutics Reports Quarterly Financials
Bulls Say, Bears Say
Bulls Say
Strategic CollaborationsCollaboration with Eli Lilly and the Rett Syndrome Research Trust may lead to further advancements and financial benefits, positioning the company for potential success.
Technology ValidationEditing profiles in iPSC derived neurons and cerebral organoids further validate the partnership with the Rett Syndrome Research Trust, highlighting the platform's versatility.
Therapeutic PotentialAxiomer platform’s potential to target CNS diseases looks promising, offering a new avenue for treating these challenging conditions.
Bears Say
Clinical DataThe lower GalNAc editing in mice for PRQR’s candidate fell below the target range and what competitors like Korro have reported, potentially raising concerns about its efficacy.
Competitive PositionPRQR's recent data presentation suggests it may be lagging behind competitors in editing efficiency, which could impact investor confidence and the stock's value.
Stock PerformancePRQR shares were down after the presentation, which may be attributed to editing efficiency issues.
---
Ownership Overview
0.00%
Insiders
0.82% Mutual Funds
19.05% Other Institutional Investors
80.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRQR FAQ
What was ProQR’s price range in the past 12 months?
ProQR lowest stock price was $1.11 and its highest was $3.29 in the past 12 months.
What is ProQR’s market cap?
Currently, no data Available
When is ProQR’s upcoming earnings report date?
ProQR’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were ProQR’s earnings last quarter?
ProQR released its earnings results on Aug 08, 2024. The company reported -$0.033 earnings per share for the quarter, beating the consensus estimate of -$0.139 by $0.105.
Is ProQR overvalued?
According to Wall Street analysts ProQR’s price is currently Undervalued.
Does ProQR pay dividends?
ProQR does not currently pay dividends.
What is ProQR’s EPS estimate?
ProQR’s EPS estimate is -$0.12.
How many shares outstanding does ProQR have?
ProQR has 81,680,200 shares outstanding.
What happened to ProQR’s price movement after its last earnings report?
ProQR reported an EPS of -$0.033 in its last earnings report, beating expectations of -$0.139. Following the earnings report the stock price went up 12.568%.
Which hedge fund is a major shareholder of ProQR?
Among the largest hedge funds holding ProQR’s share is Gilder Gagnon Howe & Co LLC.. It holds ProQR’s shares valued at N/A.
---
ProQR Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (177.78% Upside)
$5.00 (177.78% Upside)
Hedge Fund Trend
Decreased
By 97.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.1%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.66%
12-Months-Change
Fundamentals
Return on Equity
-50.85%
Trailing 12-Months
Asset Growth
-21.64%
Trailing 12-Months
Company Description
ProQR
ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.
---
PRQR Stock 12 Month Forecast
Average Price Target
$5.00
▲(177.78% Upside)
Technical Analysis
Best Analysts Covering PRQR
1 Year
1 Year Success Rate
9/23 ratings generated profit
1 Year Average Return
-20.64%
reiterated a buy rating last month
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 39.13% of your transactions generating a profit, with an average return of -20.64% per trade.
---